HighMark Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

HighMark Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-28	Closed	-$885	–	594
2023 Q3	$885	Hold	28	–	–	﹤0.01%	508
2023 Q2	$1.14K	Hold	28	–	–	﹤0.01%	496
2023 Q1	$1.04K	Hold	28	–	–	﹤0.01%	539
2022 Q4	$977	Hold	28	–	–	﹤0.01%	478
2022 Q3	$2K	Hold	28	–	–	﹤0.01%	434
2022 Q2	$1K	Hold	28	–	–	﹤0.01%	485
2022 Q1	$2K	Hold	28	–	–	﹤0.01%	451
2021 Q4	$3K	Hold	28	–	–	﹤0.01%	410
2021 Q3	$1K	Buy	+28	New	+$4.24K	﹤0.01%	483

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

HighMark Wealth Management's NTLA Position: Q4 2023 in Review

HighMark Wealth Management sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 28 shares — an estimated $885 sold.

HighMark Wealth Management first reported a position in NTLA in Q3 2021 and held it in 9 quarters. The position peaked at $3K in Q4 2021. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

HighMark Wealth Management reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
HighMark Wealth Management sold 28 Intellia Therapeutics shares in Q4 2023, an estimated $885.
HighMark Wealth Management first reported a position in Intellia Therapeutics in Q3 2021 and held it in 9 quarters.
HighMark Wealth Management's Intellia Therapeutics position peaked at $3K in Q4 2021.
292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on HighMark Wealth Management's 13F filing for Q4 2023, filed 23 Jan 2024.